文献速递甲状腺核医学核素与放射性配体治疗

甲状腺激素撤退较重组人促甲状腺激素刺激在分化型甲状腺癌转移灶中产生更高的131I吸收剂量:来自大型124I PET/CT剂量学队列的证据

Thyroid Hormone Withdrawal Yields Higher 131I Absorbed Dose to Metastases Than rhTSH Stimulation in Differentiated Thyroid Cancer: Evidence from a Large 124I PET/CT Dosimetry Cohort.
PubMed 文献 · J Nucl Med · 2025-11-03

该回顾性研究纳入367例分化型甲状腺癌患者,比较甲状腺激素撤退(THW)与重组人促甲状腺激素(rhTSH)刺激下预测的131I病灶吸收剂量。结果显示转移灶在THW后吸收剂量显著更高,而甲状腺残留组织吸收剂量两种方法无显著差异。作者认为数据支持在高转移风险患者中使用THW,但需大型患者内研究进一步验证。

要点

  • 颈淋巴结转移灶和远处转移灶的131I预测吸收剂量在THW后显著高于rhTSH刺激。
  • 甲状腺残留组织的吸收剂量在两种刺激方法间无显著差异。
  • 作者认为数据支持高转移风险患者使用THW,但需患者内研究进一步验证。

局限性

  • 本研究为患者间比较。
  • 作者指出需要大型患者内研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Achieving an optimal 131I absorbed dose in differentiated thyroid carcinoma lesions is crucial for the success of radioiodine therapy. Sufficient thyroid-stimulating hormone (TSH) stimulation before radioiodine therapy can be achieved with either thyroid hormone withdrawal (THW) or by injection of recombinant human TSH (rhTSH). We compared the predicted 131I lesion absorbed dose between THW and rhTSH stimulation in patients assessed by pretherapeutic 124I PET/CT dosimetry. Methods: This retrospective study included patients with differentiated thyroid carcinoma who had undergone total thyroidectomy with or without cervical lymph node dissection and had received 124I PET/CT lesion dosimetry. All patients underwent TSH stimulation with either rhTSH injection or THW. For lesion dosimetry, 2 124I PET/CT examinations were performed after 124I administration. Using 124I PET data, the lesion absorbed dose per unit of administered activity (LDpA) of 131I was calculated for each lesion. Patients and lesions were categorized by the TSH stimulation method used and the clinical indication for dosimetry (adjuvant, residual/recurrent, or metastatic disease). Lesions were further categorized by location (thyroid remnants, cervical lymph node metastases, or distant metastases). Results: In total, 453 dosimetry cycles and 949 lesions were analyzed in 367 patients. TSH levels were significantly higher after rhTSH stimulation in the overall patient group (P < 0.001) and across all subgroups (P = 0.038 for adjuvant; P = 0.002 for residual/recurrent; P < 0.001 for metastatic). Thyroglobulin levels were significantly elevated after rhTSH stimulation in both the overall patient group (P < 0.001) and the metastatic subgroup (P = 0.030). LDpA values were significantly higher after THW in the overall patient group (P < 0.001) and in the adjuvant subgroup (P = 0.049). LDpA values of thyroid remnants did not significantly differ between both stimulation methods. Conversely, LDpA values were significantly higher after THW in cervical lymph node (P = 0.005) and distant (P = 0.001) metastases. Conclusion: As assessed by pretherapeutic 124I PET/CT dosimetry, absorbed doses to metastatic lesions were higher after THW compared with rhTSH, whereas absorbed doses of thyroid remnants were comparable between both stimulation methods. In this interpatient comparison, data support the use of THW in patients with an elevated risk of metastatic disease; however, a large intrapatient study is warranted for further validation.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Čiučiulkaitė I, Zuccotti GA, Jallo C, et al. Thyroid Hormone Withdrawal Yields Higher 131I Absorbed Dose to Metastases Than rhTSH Stimulation in Differentiated Thyroid Cancer: Evidence from a Large 124I PET/CT Dosimetry Cohort. J Nucl Med. 2025. PMID: 40998731. doi:10.2967/jnumed.125.270391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。